R&G PharmaStudies Co., Ltd. (SZSE:301333) announces a share repurchase program. Under the program, the company will repurchase up to CNY 80 million worth of its A shares. The shares will be purchased at a price not exceeding CNY 58 per share. The repurchased shares will be used for the implementation of ESOP or equity incentive plan. The program will be funded from company's own funds. The program will be valid for 12 months.

On July 10, 2024, the company amended its share repurchase program. The shares will be repurchased at a price not exceeding CNY 57.8 per share.